secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K/A
Filed at:   2024-01-17T23:59:59+00:00
Accession:  0001213900-24-004199
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC BioPharma amends convertible note; corrects conversion price, discloses placement agent warrants
--------------------------------------------------------------------------------

- Secured convertible note $1.2M principal issued to Lind Global Fund II for $1M purchase price.
- Conversion price amended to lesser of $3.50 fixed or 90% of avg of three lowest VWAPs in prior 20 days.
- First 180 days conversions at fixed $3.50 price if no event of default, per amendment dated Jan 12, 2024.
- Issued Allele Capital placement agent warrants for 30,000 shares at $2.00 per share.
- Lender waives any prior events of default under the transaction documents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390024004199/0001213900-24-004199-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390024004199/ea191466-8ka1_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-004199

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer